← Research library

Semax in acute hemispheric ischemic stroke: 1997 clinical and EEG comparison

Controlled study in people · 1997

What was studied
110 people, 30 Semax plus usual care and 80 usual-care controls. Moderate stroke: 16 vs 55. Severe stroke: 14 vs 25 (Table 1).
Main finding
In moderate stroke, the day-6 Scandinavian Stroke Scale gain was 13.0 vs 8.45 points with Semax versus control. Day-21 gains were 21.4 vs 17.2, with no significant difference marked for that time point.

Reported findings and study design

30 Semax-treated patients and 80 conventional-care controls. Clinical and electrophysiological observations included the Scandinavian, Orgogozo and original clinical scales.

Population or model 110 people, 30 Semax plus usual care and 80 usual-care controls. Moderate stroke: 16 vs 55. Severe stroke: 14 vs 25 (Table 1).

Dose, route and schedule

The Neurology Bulletin full text reports 12, 18 or 24 mg/day intranasally in two administrations for the first five days. The companion abstract reports 12 and 18 mg/day and mentions five- and ten-day courses. The numerical results table comes from the five-day full-text report.

Protocol source ↗ · Neurology Bulletin full text and indexed Korsakov companion abstract

Results · Neurology Bulletin full text, Tables 1–2, and the indexed Korsakov companion abstract.
MeasureResultComparison, timing and statistics
Scandinavian Stroke Scale gain, moderate stroke+13.0 vs +8.45 points16 Semax vs 55 controls · Day 6 · p<0.05
Scandinavian Stroke Scale gain, severe stroke+11.3 vs +1.0 points14 Semax vs 25 controls · Day 6 · p<0.001
Changes from baseline by clinical scale (Table 1)
Changes from baseline by clinical scale (Table 1)
Severity / scaleDay 6 Semax vs controlDay 21 Semax vs control
Moderate / Scandinavian+13.0 vs +8.45+21.4 vs +17.2
Moderate / Orgogozo+20.0 vs +15.9+39.0 vs +29.02
Moderate / original scale+4.0 vs +2.45+5.6 vs +5.09
Severe / Scandinavian+11.3 vs +1.0+18.3 vs +13.1
Severe / Orgogozo+15.0 vs +5.5+27.5 vs +24.1
Severe / original scale+4.0 vs −0.22+6.67 vs +7.0

Point changes as reported. No significant between-arm effects are marked at day 21 in Table 1. Table 2 has a conflicting severe-control denominator.

The day-6 signal comes from a historical comparison with unresolved allocation and masking. The probable 1997 Korsakov companion publication is indexed as PMID 11517472.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • Allocation and masking are unclear. Systematic adverse-event data are unavailable in the checked sections.
  • Matching authors and 30/80 enrollment indicate probable overlap with the 1997 Korsakov paper. The source record treats the two as companion reports.
  • The digitized Table 2 lists a severe-control number inconsistent with Table 1. The extracted results use Table 1. The Cerebrolysin and Cronassial comparisons are historical.

Related publications may describe some of the same participants or experiments.

Source details

Journal article · Journal article

Neurology Bulletin full text, Tables 1–2, and the indexed Korsakov companion abstract.

Indexed abstract

Sources checked

Citation

Clinical trial / comparisonFull text available

E. I. Gusev, V. I. Skvortsova, E. Iu. Zhuravleva, A. V. Vanichkin. Semax in acute hemispheric ischemic stroke: 1997 clinical and EEG comparison Neurology Bulletin. 1997;29(3–4):32–38. Related 1997 Korsakov publication: PMID 11517472.

Study source ↗ · DOI 10.17816/nb80150 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards